---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-23-000014"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:57:35.773474+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolent Health Q4 revenue up 54% to $382.4M; new partnerships to add $250M+ in 2024

## Summary
- Q4 revenue $382.4M (+54% YoY); net loss $11.3M; Adjusted EBITDA $32.3M (8.4% margin).
- Full year 2022 revenue $1,352M (+48.9% YoY); net loss $19.2M; Adjusted EBITDA $106.3M (7.9% margin).
- Total Lives on Platform 20.6M as of Dec 31, 2022, up from 17.7M a year ago.
- New Performance Suite deal with 5th largest US health insurer for oncology in FL/AZ, expected to drive >$250M revenue in 2024.
- New risk-based agreement with large regional health plan within Evolent Care Partners.

## SEC filing metadata
- accession: 0001628908-23-000014
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/0001628908-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/evh-20230222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-23-000014
- JSON: https://secwatch.observer/filing/0001628908-23-000014.json
- Plain text: https://secwatch.observer/filing/0001628908-23-000014.txt

## Key facts
- Earnings Releases
  Evolent Health, Inc. reported Quarter ended December 31, 2022 results: revenue $382.4 million, net income $11.3 million.
  - Period: Quarter ended December 31, 2022
  - Revenue: $382.4 million
  - Net income: $11.3 million
  - Result: reported results
  source text: Quarter ended December 31, 2022: • Revenue of $382.4 million, an increase of $134.1 million, or 54.0%, from the three months ended December 31, 2021. • Net loss attributable to common shareholders of Evolent Health, Inc. of $11.3 million resulting in a net loss margin of (3.0)%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/0001628908-23-000014-index.htm
- Earnings Releases
  Evolent Health, Inc. reported Full year ended December 31, 2022 results: revenue $1,352.0 million, net income $19.2 million.
  - Period: Full year ended December 31, 2022
  - Revenue: $1,352.0 million
  - Net income: $19.2 million
  - Result: reported results
  source text: Full year ended December 31, 2022: • Revenue of $1,352.0 million, an increase of $444.1 million, or 48.9%, from the year ended December 31, 2021. • Net loss attributable to common shareholders of Evolent Health, Inc. of $19.2 million resulting in a net loss margin of (1.4)%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/0001628908-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.